Background and Objectives: Medication adherence is a key determinant of treatment effectiveness in early-stage breast cancer, particularly during long-term systemic therapies. As breast cancer is increasingly diagnosed at younger ages, a growing number of women continue to carry active parenting responsibilities during treatment. However, the associations between parenting-related psychosocial factors and medication adherence remain insufficiently explored. This study aimed to examine the associations between parenting stress, spiritual well-being, and medication adherence in women with early-stage breast cancer who maintain active parenting roles. Materials and Methods: This multicenter, cross-sectional study included 432 women with early-stage (I–III) breast cancer receiving active systemic therapy across nine oncology centers. Parenting stress was assessed using the Parenting Stress Scale (PSS), spiritual well-being using the Functional Assessment of Chronic Illness Therapy–Spiritual Well-Being Scale (FACIT-Sp-12), and medication adherence using the 6-item Modified Morisky Adherence Scale (MMAS-6). Spearman correlation analyses and multivariable linear regression models were used to evaluate associations between variables. Mediation analysis was performed using Hayes’ PROCESS macro (Model 4) with 5000 bootstrap samples to assess statistical mediation. Results: Parenting stress was positively associated with poorer medication adherence (ρ = 0.248, p < 0.01), whereas spiritual well-being was negatively associated with non-adherence (ρ = −0.225, p < 0.01). Parenting stress showed a strong inverse association with spiritual well-being (ρ = −0.597, p < 0.01). In multivariable regression analyses, both parenting stress and spiritual well-being were independently associated with medication adherence (β = 0.180, p = 0.002 and β = −0.199, p = 0.001, respectively). Mediation analysis demonstrated a significant indirect statistical association between parenting stress and medication adherence through spiritual well-being (indirect effect = 0.0155), consistent with partial statistical mediation. Conclusions: Medication adherence among women with early-stage breast cancer and active parenting responsibilities is associated with psychosocial context in addition to clinical factors. Parenting stress is associated with poorer adherence, whereas greater spiritual well-being is associated with better adherence within a statistical mediation framework. These findings generate hypotheses for future longitudinal and interventional studies.
Meme kanseri, erken tanı ve modern tedaviler sayesinde uzun dönem sağkalım oranları artmış bir malignitedir. Bu nedenle tedavi sonrası izlem ve yaşam boyu takip önem kazanmıştır. İzlemde temel hedef yalnızca rekürrens taraması değil; geç toksisitelerin, sekonder malignitelerin ve yaşam kalitesinin değerlendirilmesidir. Klinik takip sıklığı ilk yıllarda daha yoğundur ve yıllık mamografi meme koruyucu cerrahi yapılan hastalarda devam eder. Tedaviye bağlı geç toksisiteler arasında kardiyotoksisite, pulmoner fibroz, nöropati, kemik sağlığının bozulması ve menopoza bağlı semptomlar yer alır. Aromataz inhibitörleri osteoporoz riskini artırırken tamoksifen endometriyal kanser ve tromboemboli riskini yükseltebilir. Lenfödem, özellikle aksiller diseksiyon ve radyoterapi sonrası gelişebilen önemli bir morbidite kaynağıdır ve manuel drenaj ile kompresyon tedavisi temel yaklaşımdır. Sekonder malignitelerin erken tanısı için kişiselleştirilmiş tarama protokolleri gereklidir. Genetik yatkınlığı olan hastalarda (BRCA vb.) aile taraması ve risk azaltıcı stratejiler önem taşır. Egzersiz, kilo kontrolü ve sigarasız yaşam, rekürrens riskini azaltmada etkilidir. Multidisipliner survivorship yaklaşımı, uzun dönem yaşam kalitesini artırmada temel rol oynar.
Meme kanseri, kadınlarda en sık görülen malignitelerden biri olup, hastalığın önlenmesi ve prognozunun iyileştirilmesinde yaşam tarzı faktörleri belirleyici bir rol oynamaktadır. Düzenli fiziksel aktivite, meme kanseri riskini %20–40 oranında azaltmakta; egzersiz, östrojen düzeylerini düşürerek özellikle hormon duyarlı tümörlerde sağkalımı iyileştirebilmektedir. Obezite, inflamasyon ve artmış östrojen üretimi yoluyla kötü prognozla ilişkilidir. Adipokinler (adiponektin ve leptin), tümör mikroçevresinde proliferasyon ve anjiyogenezi düzenleyen temel biyomoleküllerdir. Diyabet, insülin direnci ve metabolik sendrom, hiperinsülinemi ve IGF-1 aracılı sinyal yolları üzerinden kanser riskini artırmaktadır. Ayrıca bağırsak mikrobiyotasındaki bozulmalar östrojen metabolizmasını ve inflamasyonu etkileyerek meme kanseri gelişimine katkıda bulunabilir. Beslenmede liften zengin, sebze ve meyve ağırlıklı diyetler koruyucu etki gösterirken; alkol tüketimi, yüksek yağ alımı ve sigara risk faktörleridir. D vitamini eksikliğinin kanser gelişiminde rolü olabileceği düşünülmekte, ancak vitamin takviyelerinin koruyucu etkisi henüz net değildir. Uyku bozuklukları, depresyon ve sirkadiyen ritim bozuklukları da hastalığın prognozunu olumsuz etkileyebilmektedir. Sonuç olarak, düzenli egzersiz, sağlıklı beslenme, ideal kilo kontrolü, sigara ve alkolden uzak durma gibi yaşam tarzı değişiklikleri meme kanseri riskinin azaltılması ve tedavi sürecinin desteklenmesinde temel unsurlardır.
Background/Objectives: We aimed to evaluate the real-world outcomes of first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer, together with the progression patterns, including the management and outcomes of oligoprogressive disease in the real-world setting. Methods: Patients who received first-line osimertinib at 33 oncology centers across Türkiye were retrospectively analyzed. Results: The median (IQR) age of 143 patients was 59.4 (50.9–68.9), 62.9% were female, and 68.5% were non-smokers. The most frequently identified EGFR mutations were exon 19 deletion (64.3%) and exon 21 L858R (28.7%). The median progression-free survival (PFS) was 17.6 months (95% CI 14.6–20.6). Exon 19 deletion subgroup had significantly longer median PFS than exon 21 L858R subgroup (22.0 vs. 11.7 months; HR = 0.40 [95% CI 0.25–0.64]; p < 0.001). Of the patients who experienced disease progression, 51.2% had oligoprogression. Among these, 81.8% received local ablative treatments (LATs) while continuing osimertinib. The median time to osimertinib discontinuation was significantly longer in patients treated with LATs than in those who continued osimertinib without LATs (8.5 vs. 3.0 months; p = 0.001). In the overall cohort, 12- and 24-month overall survival (OS) rates were 93.0% and 82.5%, respectively. The median OS was significantly longer in patients with oligoprogression compared to those with systemic progressive disease (57.7 vs. 36.5 months; p = 0.007). Any-grade and grade ≥ 3 osimertinib-related adverse events occurred in 55.2% and 6.3% of patients, respectively. Conclusions: This study supports the real-world effectiveness and tolerability of first-line osimertinib. Oligoprogression was associated with longer OS compared with systemic progression, and the integration of LATs in carefully selected patients with oligoprogression may be associated with prolonged osimertinib treatment duration and favorable post-progression outcomes.
Background/Objectives: Despite improved survival with immune checkpoint inhibitors, the optimal treatment after anti-PD-1 progression in metastatic melanoma remains unclear. This study compared survival outcomes and treatment responses between chemotherapy (CT)- and immunotherapy (IO)-based therapies administered after nivolumab progression in patients with BRAF-negative metastatic melanoma. Methods: This multicenter retrospective study included patients with BRAF-negative metastatic melanoma who developed disease progression during nivolumab treatment. Post-progression systemic therapies were categorized as CT- or IO-based treatments. Treatment responses were assessed according to RECIST version 1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method, and prognostic factors were evaluated using Cox regression analyses. Results: A total of 141 patients were included. Following nivolumab progression, 107 (75.9%) received CT and 34 (24.1%) received IO. Based on best response to nivolumab, the objective response rate (ORR; CR + PR) was 55.1% in the CT group and 44.1% in the IO group. After post-nivolumab treatment, ORRs were 29.9% and 32.4% in the CT and IO groups, respectively, whereas complete response rates were higher with IO (21.2% vs. 3.0%). Median PFS was 4.17 months in the CT group and 3.9 months in the IO group (p = 0.403). Median OS was 7.83 and 8.17 months, respectively (p = 0.416). Elevated LDH level was identified as an independent adverse prognostic factor. Conclusions: In this multicenter real-world cohort, no statistically significant differences in survival were observed between patients receiving CT or IO after nivolumab progression. Given the retrospective, non-randomized study design, these findings should not be interpreted as evidence of comparative treatment efficacy. The higher CR rate observed with IO should be interpreted cautiously due to potential selection bias. Prospective studies are warranted to define the optimal treatment strategy after anti-PD-1 failure.